FDA Approvals
Eli Lilly and Bristol Myers Squibb Secure Key Neurological Approvals
Fierce Pharma
•
January 2, 2025
Eli Lilly's Alzheimer's treatment Kisunla and Bristol Myers Squibb's schizophrenia drug Cobenfy received FDA approval in 2024, offering significant advancements in treating neurological conditions.
Two pivotal FDA approvals in 2024 addressed major unmet needs in neurology. Eli Lilly's Kisunla, approved in July, provides a new treatment option for Alzheimer's disease. Similarly, Bristol Myers Squibb's Cobenfy, approved in September, offers a new approach to treating schizophrenia. Both approvals represent significant breakthroughs for patients suffering from these debilitating conditions which currently lack sufficient effective treatments, impacting millions who are underserved by existing therapies.